Taigen Biopharmaceuticals Holdings Ltd (4157) — Capital Reinvestment Ratio
Taigen Biopharmaceuticals Holdings Ltd (4157) has a Capital Reinvestment Ratio of 0.16x as of March 2026, meaning it reinvests 0% of its operating cash flow (NT$111.04 Million) in capital expenditures (NT$18.13 Million). Check Taigen Biopharmaceuticals Holdings Ltd (4157) tangible net worth to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Taigen Biopharmaceuticals Holdings Ltd Capital Reinvestment Ratio (2021–2025)
This chart tracks Taigen Biopharmaceuticals Holdings Ltd's Capital Reinvestment Ratio across 3 annual periods. For the full cash flow conversion analysis, see 4157 cash flow metrics.
Annual Capital Reinvestment Ratio for Taigen Biopharmaceuticals Holdings Ltd (2021–2025)
Year-by-year Capital Reinvestment Ratio for Taigen Biopharmaceuticals Holdings Ltd from 2021 to 2025. See 4157 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.22x | NT$20.93 Million | NT$4.50 Million | ▼ -39.6% |
| 2023 | 0.36x | NT$20.74 Million | NT$7.39 Million | ▲ +1795.4% |
| 2021 | 0.02x | NT$629.07 Million | NT$11.83 Million | — |